Lung Cancer
 

Your access to vital information on lung cancer is now easier, with comprehensive coverage of this topic at your fingertips. ASCO has gathered and synthesized data on lung cancer from a multitude of key sources, including the Journal of Clinical Oncology and other ASCO publications, the Virtual Meeting, and more. Experience the ease of finding in-depth information on lung cancer topics, and visit often to remain current with timely updates.


 

 
JCO Highlighted Lung Cancer Articles Last Updated: October 20, 2009
Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non?Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics (JCO, July 2009)
Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non?Small-Cell Lung Cancer (JCO, September 2009)
Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non?Small-Cell Lung Cancer (JCO, July 2009)
Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer (JCO, October 2009)
Duration of Chemotherapy for Advanced Non?Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials (JCO, July 2009)

More >

Medline Latest Lung Cancer Articles Last Updated: November 1, 2009
Influence on the health of the partner affected by tumor disease in the wife or husband based on a population-based register study of cancer in Sweden. (J Clin Oncol, 2009 Aug)
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. (J Clin Oncol, 2009 Aug)
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. (J Clin Oncol, 2009 Aug)
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. (Clin Cancer Res, 2009 Apr)
Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment. (Clin Cancer Res, 2009 Jul)

More >

Virtual Meeting  

Presentations from the 2008 ASCO Annual Meeting

View lung cancer presentations from the 2008 ASCO Annual Meeting. In addition, search lung cancer presentations from previous meetings.

More >

Abstracts  

Abstracts from the 2008 ASCO Annual Meeting

Search the 2008 melanoma abstracts as well as abstracts back through the 2000 Annual Meeting

More >

Educational Book  

Manuscripts from the 2009 Educational Book

Find lung cancer manuscripts grouped into areas of interest, or search the 2002-2009 Educational Books archive.

More >

Cancer.Net  

Cancer.Net doctor-approved cancer information from ASCO

Find information and resources to support your patients living with lung cancer

More >

 
 
2010 AM
2010 ASCO Annual Meeting
McCormick Place – Chicago, IL
June 4 - 8, 2010



Highlights
This online resource is supported by: